BriaCell to Present Positive Clinical Data for Bria-IMT(TM) and Preclinical Data for Next Generation Bria-OTS+(TM) Personalized Immunotherapy at the 2026 AACR Conference
MWN-AI** Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, TSX: BCT) has announced its participation in the 2026 American Association for Cancer Research (AACR) Annual Meeting, where the company will present four posters highlighting promising clinical and preclinical data related to its immunotherapy developments. The conference is set to take place from April 17-22 at the San Diego Convention Center.
Among the key presentations will be findings from BriaCell's pivotal Phase 3 study of Bria-IMT, combined with an immune checkpoint inhibitor, which aims to establish its safety and efficacy for late-stage metastatic breast cancer patients. Notably, preliminary results suggest that these heavily pretreated patients maintained quality of life indicators, indicating the therapy's potential to improve treatment options for those facing limited alternatives.
Additionally, BriaCell will showcase two posters revisiting analyses of previous Phase 2 data, reinforcing the safety and efficacy of Bria-IMT. Another significant highlight is the preclinical data for Bria-OTS+, a next-generation personalized off-the-shelf immunotherapy. This innovative platform has shown promise in activating both innate and adaptive immune responses against various cancers, including breast, prostate, lung, and melanoma. The findings indicate improved efficacy and safety profiles by fostering persistent immune competence without leading to exhaustion, a common hurdle in cancer treatments.
William V. Williams, MD, President & CEO of BriaCell, expressed the company’s commitment to advancing cancer care through innovative immunotherapies, aligning with ongoing patient needs for effective treatments. Following the conference, the posters will be available online for further dissemination of this critical research. BriaCell continues to navigate a dynamic field, aiming to redefine cancer treatment approaches with its pioneering therapies.
MWN-AI** Analysis
As BriaCell Therapeutics Corp. gears up to present significant clinical and preclinical data at the 2026 American Association for Cancer Research (AACR) Annual Meeting, investors should closely monitor the implications of these developments. The presentation of data from the pivotal Phase 3 study of Bria-IMT, along with insights into the next-generation Bria-OTS+ personalized immunotherapy platform, has the potential to solidify BriaCell’s position in the biotech sector, particularly within cancer treatment.
Bria-IMT's clinical data, highlighting the preservation of quality of life (QOL) among late-stage metastatic breast cancer patients, could amplify investor confidence. As the company aims to address the urgent need for innovative cancer therapies, positive outcomes could lead to increased demand for its shares, driven by prospective partnership opportunities and heightened market interest.
Meanwhile, the preclinical data for Bria-OTS+ might illustrate the robustness of BriaCell’s immunotherapy portfolio. The indication of broad immune activation without exhaustion suggests a compelling competitive edge against an increasingly crowded market. Should these findings be robust in efficacy and safety, they could pave the way for expedited development timelines and improved valuation for the company.
As BriaCell continues to provide transparency and updates through the AACR and their scientific publications, investors may want to keep a close watch on subsequent stock movements surrounding the event. The upcoming presentations could lead to significant stock volatility based on market reactions—both positive and negative.
In conclusion, BriaCell stands at a pivotal moment; sustained positive clinical outcomes may establish it as a leader in targeted cancer therapies. Investors should consider accumulating shares ahead of the conference, given the potential for an upward trend fueled by promising data presentations. However, it is also crucial to remain vigilant of market reactions and broader industry developments post-presentation.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PHILADELPHIA and VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that it will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California. The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Abstracts will be published in the online Proceedings of the AACR.
“With four posters presenting positive clinical and preclinical data, we are expanding the body of evidence supporting the efficacy and favorable safety profile of our novel immunotherapy, with the goal of improving care for patients with cancer who remain in urgent need of new treatment options,” stated William V. Williams, MD, BriaCell’s President & CEO.
Session Title: Phase II and Phase III Clinical Trials
Session: 4/20/2026 2:00-5:00 PM
Location: Poster Section 52
Poster Board Number: 1
Poster Number: CT137
Title: QOL Outcomes in Bria-ABC Late-Stage Metastatic Phase 3 Trial
Summary: Heavily pretreated metastatic breast cancer patients in the pivotal Phase 3 study of Bria-IMT plus an immune check point inhibitor maintained overall health status and key functional measures with a favorable safety profile. These findings are encouraging because they suggest meaningful preservation of quality of life for late-stage metastatic breast cancer patients with limited treatment options.
Session Category: Clinical Research
Session Title: Vaccines and Other Immunomodulatory Agents
Session: 4/21/2026 2:00-5:00 PM
Location: Poster Section 49
Poster Board Number: 12
Poster Number: 6701
Title: Re-Engineering Cancer Vaccines: Bria-OTS+ Integrates Innate and Adaptive Immunity for Broad and Persistent Anti-Tumor Responses
Summary: Bria-OTS+ is a personalized off-the-shelf next-generation, genetically engineered whole-cell cancer immunotherapy platform designed for better efficacy and safety. Our findings indicated that Bria-OTS+ immunotherapy targeting breast, prostate, lung and melanoma activated key components of both the innate and adaptive immune system to broadly attack and destroy cancer cells. These include coordinated activation of CD4?/CD8? T, NK, NKT and B cells, increased cytokine release and persistent immune competence without exhaustion – combating a known cause of cancer progression.
Session Category: Clinical Research
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 42
Poster Board Number: 5
Poster Number: 1065
Title: Mitosis in Circulating Tumor Cells Correlates with Highly Aggressive Disease in Metastatic Breast Cancer
Session Category: Clinical Research
Session Title: Biomarkers Predictive of Therapeutic Benefit 1
Session: 4/19/2026 2:00-5:00 PM
Location: Poster Section 40
Poster Board Number: 19
Poster Number: 1025
Title: Monitoring PD-L1 in tumor macrophage fusion cells in blood identifies high PD-L1 checkpoint inhibitor responses in metastatic breast cancer
Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting four posters at the 2026 AACR, the contents of such posters, and the expected disclosure of clinical data from its ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor and preclinical data for Bria-OTS+, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ**
What potential impact could the findings from "BriaCell Therapeutics Corp. Warrant BCTXW" presentations have on the investment landscape for cancer immunotherapy companies in both Philadelphia and Vancouver?
How might the advancements from "BriaCell Therapeutics Corp. Warrant BCTXW" affect strategic partnerships or collaborations among biotech firms in Philadelphia compared to those in Vancouver?
In what ways could the data presented by "BriaCell Therapeutics Corp. Warrant BCTXW" influence regulatory environments or funding opportunities for biotech companies in Philadelphia versus Vancouver?
Considering the innovations from "BriaCell Therapeutics Corp. Warrant BCTXW", what trends could emerge in healthcare investments in both Philadelphia and Vancouver as a result of the findings presented at the 2026 AACR?
**MWN-AI FAQ is based on asking OpenAI questions about BriaCell Therapeutics Corp. Warrant (NASDAQ: BCTXW).
NASDAQ: BCTXW
BCTXW Trading
-27.78% G/L:
$0.0013 Last:
180,239 Volume:
$0.0018 Open:
